News for MediWound Ltd. (MDWD)

MediWound Ltd (MDWD) is set to release its Q4 2024 earnings on Mar 19, 2025. The consensus estimate for Q4 2024 revenue is $5.14 million, and the earnings are e

Q4 2024 Revenue: $5.8 million, up from $5.3 million in Q4 2023.Q4 2024 Gross Profit: $0.9 million with a gross margin of 15.5%, up from $0.7 million and a 13.5

Mar 19, 2025 / 12:30PM GMTOperator Good day, and welcome to MediWound's sports quarter and full year 2024 earnings conference call (Operator Instructions) Pleas

MediWound Ltd. (NASDAQ:MDWD) Q4 2024 Results Conference Call March 19, 2025 8:30 AM ETCompany ParticipantsDan Ferry - IR, LifeSci AdvisorsOfer Gonen - Chief...

Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers Expanded strategic research collaborations with industry leaders, now inc

**media[570626]**

CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (VCEL), a leader in advanced therapies for the sports medicine and severe burn care m

Conference call and webcast scheduled for Wednesday, March 19th at 8:30 a.m. Eastern Time YAVNE, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Full-Year Total Revenue Growth of 20% to $237.2 Million, with MACI Revenue Growth of 20% and Burn Care Revenue Growth of 22% Full-Year Adjusted EBITDA Growth o

Findings in Burns Journal confirm NexoBrid's superiority over standard of care in pediatric patients with deep thermal burnsNexoBrid is approved for pediatric u

YAVNE, Israel, Feb. 24, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. ( MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today an

Transaction Overview On December 31, 2024, Rosalind Advisors, Inc. (Trades, Portfolio) made a strategic move by acquiring an additional 9,536,647 shares in Biof

**media[538614]**

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of

On December 31, 2024, Rosalind Advisors, Inc. (Trades, Portfolio) made a significant move by adding 412,087 shares of OptiNose Inc. (NASDAQ: OPTN) to its portfo

Full-Year 2024 Total Revenue Growth of 20% and Adjusted EBITDA Growth of Approximately 55% MACI Full-Year 2024 Revenue Growth of 20%, with Fourth Quarter Reven

**media[515144]**

**media[509425]**